A Phase II Study of Estramustine, Docetaxel, and Carboplatin With G-CSF Support in Men With Hormone Refractory Prostate Cancer
OBJECTIVES: I. Determine the response rate (objective and PSA response) and duration of
response to estramustine, docetaxel, and carboplatin with filgrastim (G-CSF) support in
patients with hormone refractory prostate cancer. II. Determine the toxicity of this regimen
in this patient population.
OUTLINE: Patients receive oral estramustine 3 times daily on days 1-5. Patients receive
docetaxel IV over 1 hour followed by carboplatin IV over 1 hour on day 2. Filgrastim (G-CSF)
SC is administered beginning on day 6 and continuing until hematopoietic recovery. Treatment
continues every 21 days in the absence of unacceptable toxicity or disease progression.
Patients are followed every 3 months for a maximum of 2 years.
PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study within 10 months.
Primary Purpose: Treatment
William Oh, MD
Dana-Farber Cancer Institute
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|
|University of Chicago Cancer Research Center||Chicago, Illinois 60637|
|Lineberger Comprehensive Cancer Center, UNC||Chapel Hill, North Carolina 27599-7295|
|UCSF Cancer Center and Cancer Research Institute||San Francisco, California 94115-0128|
|Marlene & Stewart Greenebaum Cancer Center, University of Maryland||Baltimore, Maryland 21201|
|Norris Cotton Cancer Center||Lebanon, New Hampshire 03756|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|